ReviewStem cell reviews and reports2013
Mesenchymal stem cells as a treatment for peripheral arterial disease: current status and potential impact of type II diabetes on their therapeutic efficacy.
Review in Stem cell reviews and reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Trial
- Advances in the Role of Adipose Tissue in Promoting Injury Repair and Resist Infection.Immunity, inflammation and disease · 2026Review
- Review
- Secretome of Hypoxia-Preconditioned Mesenchymal Stem Cells Enhance Angiogenesis in Diabetic Rats with Peripheral Artery Disease.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2023Article
- Current and Novel Emerging Medical Therapies for Peripheral Artery Disease: A Literature Review.Advanced pharmaceutical bulletin · 2023Review
- Micro RNA based MSC EV engineering: Targeting the BMP2 cascade for bone repair.Frontiers in cell and developmental biology · 2023Article
- BM-MSCs alleviate diabetic nephropathy in male rats by regulating ER stress, oxidative stress, inflammation, and apoptotic pathways.Frontiers in pharmacology · 2023Article
- Safety of autologous intramuscular platelet lysate injections in patients with critical limb ischaemia: A pilot, exploratory study.The Indian journal of medical research · 2022Article
- Intravascular Application of Labelled Cell Spheroids: An Approach for Ischemic Peripheral Artery Disease.International journal of molecular sciences · 2021Article
- The neovascularization effect of dedifferentiated fat cells.Scientific reports · 2020Article
- Fabrication of New Hybrid Scaffolds forFrontiers in cardiovascular medicine · 2020Article
- Can mesenchymal stem cell lysate reverse aging?Aging · 2018Article
- Allogeneic Mesenchymal Stromal Cells (MSCs) are of Comparable Efficacy to Syngeneic MSCs for Therapeutic Revascularization in C57BKSdb/db Mice Despite the Induction of Alloantibody.Cell transplantation · 2018Article
- The Angiogenic Chemokines Expression Profile of Myeloid Cell Lines Co-Cultured with Bone Marrow-Derived Mesenchymal Stem Cells.Cell journal · 2018Article
- IFN-γ and TNF-α Pre-licensing Protects Mesenchymal Stromal Cells from the Pro-inflammatory Effects of Palmitate.Molecular therapy : the journal of the American Society of Gene Therapy · 2018Article
- Human Gingiva-Derived Mesenchymal Stem Cells Modulate Monocytes/Macrophages and Alleviate Atherosclerosis.Frontiers in immunology · 2018Article
- Considerations on the harvesting site and donor derivation for mesenchymal stem cells-based strategies for diabetes.CellR4-- repair, replacement, regeneration, & reprogramming · 2017Article
- Advances in bone marrow stem cell therapy for retinal dysfunction.Progress in retinal and eye research · 2017Review
- Therapeutic angiogenesis induced by human umbilical cord tissue-derived mesenchymal stromal cells in a murine model of hindlimb ischemia.Stem cell research & therapy · 2016Article
- Vascular stem cells-potential for clinical application.British medical bulletin · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Mesenchymal stem cells (MSCs), due to their paracrine, transdifferentiation, and immunosuppressive effects, hold great promise as a therapy for peripheral arterial disease. Diabetes is an important risk factor for peripheral arterial disease; however, little is known of how type II diabetes affects the therapeutic function of MSCs. This review summarizes the current status of preclinical and clinical studies that have been performed to determine the efficacy of MSCs in the treatment of peripheral arterial disease. We also present findings from our laboratory regarding the impact of type II diabetes on the therapeutic efficacy of MSCs neovascularization after the induction of hindlimb ischemia. In our studies, we documented that experimental type II diabetes in db/db mice impaired MSCs' therapeutic function by favoring their differentiation towards adipocytes, while limiting their differentiation towards endothelial cells. Moreover, type II diabetes impaired the capacity of MSCs to promote neovascularization in the ischemic hindlimb. We further showed that these impairments of MSC function and multipotency were secondary to hyperinsulinemia-induced, Nox4-dependent oxidant stress in db/db MSCs. Should human MSCs display similar oxidant stress-induced impairment of function, these findings might permit greater leverage of the potential of MSC transplantation, particularly in the setting of diabetes or other cardiovascular risk factors, as well as provide a therapeutic approach by reversing the oxidant stress of MSCs prior to transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.